title: Bisphosphonate therapy and atypical fractures.
abstract: Atypical femoral fractures have attracted a great deal of attention and controversy in the osteoporosis community because of their association with prolonged bisphosphonate therapy. The purpose of this article is to review the epidemiologic evidence linking bisphosphonates to atypical fractures and to highlight the potential pathologic mechanisms involved in such fractures. A management plan is provided based on the available evidence.
authors.affiliation: Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY 10021, USA.
authors.forename: Anas
authors.initials: A
authors.lastname: Saleh
authors.forename: Vishal V
authors.initials: VV
authors.lastname: Hegde
authors.forename: Anish G
authors.initials: AG
authors.lastname: Potty
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Lane
mesh_terms: D000368:Aged; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D005264:Femoral Fractures / Q000139:chemically induced* / Q000503:physiopathology; D006620:Hip Fractures / Q000139:chemically induced*; D006621:Hip Joint / Q000000981:diagnostic imaging; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D011859:Radiography; D019379:Teriparatide / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019379:Teriparatide